This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): MK-0517, ONO-7847, fosaprepitant dimeglumine, Emend IV, Ivemend (EU), Proemend
BioMedTracker has separate drug profiles for the oral and intravenous formulations of Emend. Please also see Emend (oral).
MK-0517 is an intravenous (IV) prodrug formulation of Emend (aprepitant), a substance P/neurokinin 1 (NK1) receptor antagonist. The active ingredient is fosaprepitant dimeglumine.
Ono and Merck
In November 2004, Ono signed an agreement with Merck to out-license ONO-2506 (injectable formulation), a novel compound originally synthesized and developed by Ono for the treatment of acute stroke. Under this arrangement, Ono will receive rights to MK-0431 and to aprepitant (MK-0869) for the treatment of cancer chemotherapy-induced nausea and vomiting from Merck.
Ono granted Merck an exclusive license for development and marketing of ONO-2506 (injectable formulation) and its backup compound in countries around the world (excluding Japan, South Korea and Taiwan). Under the terms of the agreement, Ono will receive an initial payment and milestone payments in addition to royalties on net sales of ONO-2506 (injectable formulation). If Merck obtains additional indications and/or products under the license, Ono will receive additional milestone payments. Ono will supply the drug to Merck as unpackaged product.
Partners: Ono Pharmaceutical Company, Ltd.
Emend (IV) News
Pink Sheet Emend Clinical Protocols
Additional information available to subscribers only: